SILVER SPRING, MD -- (Marketwired) -- 10/09/13 --
Nuvilex, Inc. (OTCQB: NVLX) (Company), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, would like to inform shareholders that its Chief Operating Officer, Dr. Gerald Crabtree, has been interviewed by Stock Market Media Group. In the interview, to be released on the firm's website the week of October 14, 2013, Dr. Crabtree discusses a number of topics, including the Company's recent restructuring, the Company's acquisition of the live-cell encapsulation-based technology for the treatment of all forms of cancer and the Company's future Phase 3 clinical trials for the treatment of advanced, inoperable pancreatic cancer.
Pat Gruden, Nuvilex's Chairman of the Board, said that, "Last week's Forbes article, Biotechs Are Back in Favor Amid Plethora of Positive Developments, (http://www.forbes.com/sites/genemarcial/2013/09/23/biotechs-are-back-in-favor-amid-plethora-of-positive-developments) which discussed Nuvilex's work, was a great opportunity to garner attention for a much needed treatment for advanced, inoperable pancreatic cancer." Ms. Gruden went on to say, "We are pleased that the press representing the business community is recognizing the work we are accomplishing with respect to our exclusive rights to a ground-breaking targeted drug delivery system that may be used to develop treatments for many types of cancer. As the Forbes story so aptly reported in its September 23rd issue, results for highly successful Phase 2 clinical trials using this technology to treat inoperable pancreatic cancer included median survival time and one-year survival rate that were better than those reported for the three pancreatic cancer chemotherapy treatments approved by the FDA. The results of those Phase 2 trials were achieved using lower than standard ifosfamide doses, which markedly reduced the side effects from the anticancer drug."
The comprehensive Forbes story also reported that Nuvilex recently announced an agreement with Fisher BioServices, a unit of Thermo Fisher Scientific, for the long-term storage of cells that will be required for Nuvilex's Phase 3 clinical trials. Nuvilex's President and CEO, Dr. Robert F. Ryan, told Forbes, "By partnering with Thermo Fisher, Nuvilex has a 'safety net' in the event any problems that might occur with the cells being prepared for clinical trials. The Company will continue to employ the most stringent and prudent criteria in selecting entities to assist us in preparing for future clinical trials."
In mid-September, 2013, Nuvilex signed an agreement with Inno Biologics, a partner of Germany's Boehringer Ingelheim, to generate cell clones for the Phase 3 trials. As mentioned by Rob Goldman of Goldman SmallCap Research, following an interview with Dr. Ryan, of the clones being generated by Inno Biologics, those with the greatest capability to convert the cancer prodrug ifosfamide into its cancer-killing form will be propagated and prepared for encapsulation. The treatment to be used in Nuvilex's Phase 3 trials will combine these encapsulated cells and ifosfamide.